{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 69,
  "pageCount": 415,
  "prevPage": 68,
  "nextPage": 70,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses direct quotes from an expert to undermine the value proposition of the subject company's product.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/69",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-69",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Slammed Vykat’s cost as unjustifiable versus generic diazoxide or its inexpensive Proglycem version",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b29a-be181fd6d9fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.07,
        "y": 0.16
      },
      "kind": "list",
      "text": "Stated that Vykat’s extended-release tablet formulation claims lack credibility; that it makes no sense versus generic diazoxide which is perfectly substitutable and which endocrinologists have used “for many years”...",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "716ff733-aa5f-4743-b08e-df88227241cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.07,
        "y": 0.43
      },
      "kind": "list",
      "text": "Slammed Vykat’s cost as unjustifiable versus generic diazoxide or its inexpensive Proglycem version – “absolutely outrageous...my concern is certainly, is this cost-effective...very expensive for a drug that isn’t that novel...it’s hard to justify.”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "896f58b0-3ba2-43a7-8c91-34fbde113051",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.07,
        "y": 0.53
      },
      "kind": "list",
      "text": "Prefers the generic suspension formulation over a tablet anyway – “I can titrate it better...most of my patients who are on diazoxide take the liquid...only a couple of patients who take the capsules”; “...why don’t I just trial regular diazoxide...[it has] the same kind of pharmacological profile as DCCR...I will probably just trial normal diazoxide and see what happens.”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db340cf9-1bf2-4a04-be7a-47259ee1ca88",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“diazoxide I use regularly...is it worth the difference...it’s probably just the diazoxide, where the extended release probably makes no difference at all...half to $1 million is a bit excessive for something you could do for a year, for $1,000 at most...I’m not convinced it’s the actual choline, the extended release that makes a big difference”; “absolutely outrageous...my concern is certainly, is this cost-effective...very expensive for a drug that isn’t that novel...it’s hard to justify.” — Trial investigator #7",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b29a-c1cb407890d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c378be2-a416-4aaa-a173-651838eb1bd8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Trial investigator #7: Co-author on Soleno trial paper and a key opinion leader with ~40 PWS patients.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4486bb13-d703-4a4c-b304-a59f63aa08da",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "ceo-quote-contradiction",
      "slug": null,
      "matchId": "d25b1078-2685-463d-94d7-567f77c89580",
      "evidence": "Uses expert testimony to contradict the company's value proposition.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}